While elevated TNF-a detected at the early onset of disease is a strong indicator for the early recognition of HHV-6 reactivation, this finding also reflects important therapeutic information that could be used as an early diagnostic marker of DIHS/DRESS.
Spotlight on Horvat & Reynaud from INSERM
Branka Horvat, MD, PhD, Director of Research at the International Centre for Infectiology Research in Lyon, France (INSERM), and her doctoral student Josephine Reynaud have recently published an important paper on a new transgenic mouse model
Activation of ciHHV-6 by telomeric circle formation
Additional evidence that shortened telomeres can cause the release and possible activation of integrated HHV-6.
Measles immunosuppression may cause abortive, subclinical reactivation of HHV-6
Dr. Yoshizo Asano and colleagues in Japan report that in measles immunosuppression, cells sensitized to HHV-6B immediate early and early antigen proteins may suppress replication cycles and virus formation, resulting in an “incomplete” subclinical state of reactivation.
New HHV-6 reagent available from The HHV-6 Foundation: DR7 Mab
We are pleased to announce that with the help of a few HHV-6 specialists, especially Prof. Louis Flamand from Canada, we have generated the monoclonal antibody DR-7.
REVIEW: Important differences between the HHV-6A and HHV-6B viruses
An international group of experts summarize the significant differences between the two viruses.
Human herpesvirus replication is activated by apoptosis
A group led by Steven Zeichner has published evidence that suggests the replication of all human herpesviruses can be activated by apoptosis.
Humanized mouse model demonstrates HHV-6A infection can cause significant immune dysfunction
Could treatment of HHV-6A co-infections slow AIDS progression?
MCP-1 found elevated in the CSF of patients with HHV-6B encephalopathy
Japanese group identifies several cytokine and chemokine responses associated with HHV-6B encephalopathy.
HHV-6B infection promotes unique pro-inflammatory effects tied to neurocognitive decline and artherosclerosis
HHV-6A and HHV-6B each express distinct chemokines that are uniquely capable of activating key inflammatory cytokines.
New HHV-6B specific cellular receptor identified
CD134, a member of the TNF receptor superfamily, has now been shown as a specific entry receptor for HHV-6B.
Chlamydia infection induces activation of ciHHV-6 leading to linear and circular DNA
A laboratory at the University of Wurzburg has published evidence that Chlamydia trachomatis may induce the activation of ciHHV-6.
Why does HHV-6 reactivate preferentially in CBT?
A group from France has reported new findings which may help explain the mystery behind the increased rates of HHV-6 reactivation and encephalitis observed among umbilical cord blood transplant (CBT) patients.
Bortezomib may increase risk of HHV-6 reactivation in myeloma patients
A new study has reported that the use of Bortezomib, known commercially as Velcade, may increase the risk of HHV-6 reactivation in myeloma patients undergoing stem cell transplantation.
HHV-6 induces oxidative stress and chlamydial persistence
Findings indicate that HHV-6 infection leads to decreased glutathione production, increased oxidative stress, and induces chlamydial persistence during co-infection
